Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 8 clinical trials
featured
A Pilot Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Background: Chronic lymphocytic leukemia (CLL) and/or small lymphocytic lymphoma (SLL) are tumors of abnormal B cells that often affect elderly patients. Studies have identified critical factors required for the growth of CLL cells. First, CLL cells survive because they receive signals through the B-cell receptor. Second, CLL cells benefit from …

thrombocytopenia
monoclonal antibodies
fludarabine
anemia
fatigue
  • 69 views
  • 15 Apr, 2019
  • 1 location
Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction

improvement of Progression Free Survival (PFS) and Overall Survival (OS) in comparison with historical controls, the prognosis of patients with 17p deletion (del17p) remains a concern, as it is clearly much

  • 2 views
  • 24 Jan, 2021
  • 41 locations
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

(SLL) either in presence of 17p deletion (Cohort 1) or those who have failed a B-receptor signaling pathway inhibitor (BCRI) therapy and who have also failed were intolerant to or were unable to

chronic lymphocytic leukemia refractory
cancer
lymphoid leukemia
measurable disease
venetoclax
  • 229 views
  • 29 Apr, 2021
  • 41 locations
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

The primary purpose of this study is to evaluate the post-marketing safety of ImbruvicaTM (ibrutinib capsule 140 milligram [mg]) under actual conditions of use, and to understand the incidence of adverse events (AEs) (serious and non-serious AEs).

lymphocytic leukemia
mantle cell lymphoma
lymphoid leukemia
lymphoma
imbruvica
  • 40 views
  • 04 Jun, 2021
  • 14 locations
Ibrutinib and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia After Ibrutinib Resistance

This phase II trial studies how well the combination of ibrutinib and venetoclax works in treating patients with chronic lymphocytic leukemia whose cancer has stopped responding to ibrutinib alone. Both ibrutinib and venetoclax may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. …

neutrophil count
cancer
lymphoid leukemia
lymphoma
venetoclax
  • 0 views
  • 25 Jan, 2021
  • 3 locations
Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia

well with standard treatment and are likely to benefit from other therapies as well. The high risk patients, id est patients with 17p deletion and or TP 53 mutational status responded very well to new

  • 0 views
  • 24 Jan, 2021
  • 53 locations
Copanlisib and Nivolumab in Treating Participants With Richter's Transformation or Transformed Indolent Non-Hodgkin's Lymphoma

This phase I trial studies best dose and how well copanlisib when given together with nivolumab works in treating participants with Richter's transformation or transformed indolent non-Hodgkin's lymphoma. Copanlisib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as …

tumor cells
marginal zone lymphoma
large b-cell lymphoma
diffuse large b-cell lymphoma
copanlisib
  • 2 views
  • 19 Feb, 2021
  • 4 locations
Optimizing PTCy Dose and Timing

Background Stem cell or bone marrow transplants can cure or control blood cancers. Sometimes the donor cells see the recipient s body as foreign. This can cause complications. A high dose of the drug cyclophosphamide (PTCy) can help reduce these risks. Researchers want to see if a lower dose of …

cyclophosphamide
chronic myeloid leukemia
fludarabine
myelofibrosis
lymphoid leukemia
  • 42 views
  • 17 Jun, 2021
  • 1 location